Tramadol drug interactions
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
List of drug interactions
Use with Carbamazepine
Use with Quinidine
Use with Inhibitors of CYP2D6
Use with Cimetidine
Use with MAO Inhibitors
Use with Digoxin
Use with Warfarin Like Compounds
Use with Carbamazepine
Patients taking carbamazepine may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol concomitant administration of ULTRACET and carbamazepine is not recommended.
Use with Quinidine
Tramadol is metabolized to M1 by CYP2D6. Quinidine is a selective inhibitor of that isoenzyme; so that concomitant administration of quinidine and tramadol results in increased concentrations of tramadol and reduced concentrations of M1. The clinical consequences of these findings are unknown. In vitro drug interaction studies in human liver microsomes indicate that tramadol has no effect on quinidine metabolism.
Use with Inhibitors of CYP2D6
In vitro drug interaction studies in human liver microsomes indicate that concomitant administration with inhibitors of CYP2D6 such as fluoxetine, paroxetine, and amitriptyline could result in some inhibition of the metabolism of tramadol.
Use with Cimetidine
Concomitant administration of ULTRACET and cimetidine has not been studied. Concomitant administration of tramadol and cimetidine does not result in clinically significant changes in tramadol pharmacokinetics. Therefore, no alteration of the ULTRACET dosage regimen is recommended.
Use with MAO Inhibitors
Interactions with MAO Inhibitors, due to interference with detoxification mechanisms, have been reported for some centrally acting drugs.
Use with Digoxin
Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.
Use with Warfarin Like Compounds
Post-marketing surveillance of both tramadol and acetaminophen individual products have revealed rare
alterations of warfarin effect, including elevation of prothrombin times.
While such changes have been generally of limited clinical significance for the individual products,
periodic evaluation of prothrombin time should be performed when ULTRACET and warfarin-like
compounds are administered concurrently.
Adapted from the FDA Package Insert.